ALFA Finder| Revenue growth | 15% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margins improved 349 bps YoY to 18.09%. |
| Demand visibility | Strong pull-led growth in critical care and infertility segments. |
| Management confidence | High, citing structural pivot to IP-owned model and Indore scale-up. |
Growth
Revenue grew 15% YoY; PAT increased 82% YoY to ₹22 Cr, driven by significant margin expansion from 14.6% to 18.1%.
Outlook
Targeting 30% capacity utilization at Indore by FY26. Focused on 'First-in-India' launches and reducing Chinese API dependence.
Risks
Regulatory delays for EU-GMP/USFDA certifications at Indore; high dependence on hospital-channel execution and specialized injector training.
Last quarter's promises, checked
Delivered
- Target 30% capacity utilization at Indore by year-end → Delivered 30% (= BEAT)
- Commitment to reach Indore EBITDA breakeven by Q4 → Delivered breakeven (= BEAT)
- Guided 15% annual revenue growth → Delivered ~15% (₹820Cr to ₹940.5Cr) (= BEAT)
Partly delivered
- Guided EU-GMP certification by Q4 → Audit completed Dec 2025 but certificate still pending (= PARTIAL)
Investor Presentation filed with BSE, NSE: GUFICBIO. Summary written with AI assistance from the document.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹478.55
- Market cap
- ₹4,799 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 65.3×Sector 43.8×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.44%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Board Meeting Date
Gufic Biosciences gives notice of a board meeting on 14 November 2026 to consider unaudited standalone and consolidated quarterly results. The filing carries no financial figures or business decision.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences' tax dispute moved after the ITAT remanded matters to the Assessing Officer. The residual Rs. 11.76 lakh demand will be redetermined in fresh assessment.
- Value
- ₹0.12 Cr
Gufic BioSciences Legal & Regulatory
Gufic Biosciences disclosed an ITAT Mumbai order for AY 2023-24 that set aside the CIT(A) findings and restored the matter to the Assessing Officer. No demand arises from the order, and the tax liability will be determined after fresh assessment.
Gufic BioSciences Business Update
Gufic Biosciences reported a USFDA pre-approval inspection at its Indore facility, concluding October 23, 2026. The inspection produced three Form 483 observations, now being addressed.
Gufic BioSciences Other Announcement
Gufic Biosciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences received a favorable appellate order from the Income Tax Commissioner. This order deletes an income tax demand of Rs. 4.33 Crore.
- Value
- ₹4.33 Cr